期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

胰高血糖素样肽-1对心血管系统的作用

原文传递
导出
摘要 随着人们生活水平的提高，心血管疾病及糖尿病的发病率逐年升高。心血管疾病是导致人类死亡的首要原因，糖尿病是心血管疾病的独立危险因素。胰高血糖素样肽-1（Glucagon—likepeptide-1，
作者 孙琴 任安
机构地区 安徽医科大学附属省立医院内分泌科
出处 《中华老年医学杂志》 CAS CSCD 北大核心 2011年第8期696-699,共4页 Chinese Journal of Geriatrics
关键词 胰高血糖素样肽-1 心血管系统 心血管疾病 独立危险因素 糖尿病 生活水 发病率
分类号 R587.1 [医药卫生—内分泌]
  • 相关文献

参考文献23

  • 1Drucker D J, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase 4 inhibitors in type 2 diabetes. Lancet, 2006, 368: 1696-705.
  • 2Deacon CF,Nauck MA, Tort-Nielsen M, et al. Both subcutaneously and intravenously administered glucagon like peptide 1 are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes, 1995, 44 .. 1126-1131.
  • 3Edholm T,Cejvan K, Abdel-Halim SM, et al. The incretin hormones GIP and GLP-1 in diabetic rats: effects on insulin secretion and small bowel motility. Neurogastroenterol Motil, 2009, 21 : 313-321.
  • 4Nauck M,Frid A, Hermansen K, et al. Efficacy and safety comparison of Liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes., the LEAD (Liraglutide effect and action in diabetes)-2 study. Diabetes Care, 2009,32 =84-90.
  • 5Garber A, Henry versus glimepiride (I.EAD-3 Mono) m , double-blind, 2009,373 .. 473-481 R, Ratner R, et al. Liraglutide monotherapy for type 2 diabetes = a randomised, 52-week, phase parallel treatment.
  • 6Vilsb+ll T, Zdravkovic M, Le-Thi T, et al. Liraglutide, a long acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care, 2007,30:1608-1610.
  • 7Klonoff DC,Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for atleast 3 years. Curr Med Res Opin,2008, 24:275 286.
  • 8Astrup A, RSssner S,Van Gaal I., et al. Effects of Liraglutide in the treatment of obesity : a randomised, double-blind, placebo-controlled study. Lancet, 2009, 374, 1606 1616.
  • 9Avenell A, Broom J, Brown TJ, et al. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health TechnolAssess, 2004, 8:iii-iv, 1-182.
  • 10Ban K, Noyan-Ashraf MH, Hoefer J, et al. Cardioprotective and vasodilatory actions of glucagon- like peptide 1 receptor are mediated through bothglucagon-like peptide 1 receptordependent and - independent pathways. Circulation, 2008, 117: 2340-2350.
中华老年医学杂志
2011年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部